drugset
drugset / Trial / NCT00533351

Safety and Efficacy of AGN201781 in Neuropathic Pain

NCT00533351 ↗

Phase 2 Terminated 9 enrolled Allergan
RandomizedCrossoverTriple-blindTreatment

Summary

This study will explore the safety and efficacy of AGN201781 in patients with postherpetic neuralgia or post-traumatic peripheral neuralgia

Timeline

Start
2008-03
Primary completion
2008-06
Completion
2008-06

Outcome

Outcome not reported

Stopped (Enrollment): “This study was terminated early due to low enrollment.”

Drugs

EvaluationDrugModalityDoseRoute
Subject AGN201781 Unknown 50 mg —

Indications

neuralgia